Compare Hims and Hers Health Inc (HIMS) vs Snap Inc (SNAP) Price & Performance

Hims & Hers Health stock trades at $31.59, up 6.51% today, showing strong momentum. The technical outlook is bullish, with the price above key moving averages and support at $30. Fundamentally, revenue growth is robust at 40% year-over-year in Q2 2026 (MarketBeat, 2026-08-10), but profitability remains challenged with a net loss margin of -0.56% in 2026. The company raised its annual revenue forecast to $3.1–3.3 billion (WSJ, 2026-08-10), reflecting confidence in subscriber growth and expansion into weight-loss treatments.

The investment outlook is mixed: strong revenue growth and bullish analyst targets near $35.60 offer upside, but high valuation ratios (P/E of 57.14) and recent earnings misses heighten risk. Key risks include margin pressure from GLP-1 investments and ongoing legal investigations. Wall Street sentiment is cautious, with 65% hold ratings, suggesting patience for profitability improvements.

SNAP trades at $5.33, up 2.3% today, with a bullish technical signal and recent Q2 2026 earnings beating expectations. Revenue grew 19% year-over-year to $1.60 billion, and adjusted EBITDA surged 505%. The stock shows improving operational trends but remains unprofitable, with a net income margin of -4.9% for 2025. Analyst consensus price target is $7.02, suggesting potential upside from current levels.

Outlook hinges on sustained advertising recovery and cost discipline. Risks include persistent losses, high debt, and competitive pressure. Institutional sentiment is mixed, with 38% buy ratings but recent insider selling. The stock offers speculative growth potential if profitability improves, but volatility may persist near-term.